Latest Conference Articles

December 7th 2014, 3:25pm

ASH Annual Meeting and Exposition

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

December 7th 2014, 1:11pm

ASH Annual Meeting and Exposition

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

December 7th 2014, 11:29am

ASH Annual Meeting and Exposition

Patients with relapsed and difficult-to-treat Hodgkin lymphoma who received brentuximab vedotin had an unprecedented 50% higher likelihood of continuing to experience PFS at 2 years.

December 7th 2014, 11:06am

ASH Annual Meeting and Exposition

Two studies spotlighted at the 2014 ASH Annual Meeting characterized the efficacy of treatment with anti-CD38 monoclonal antibodies in the frontline setting and for patients with refractory disease.

December 7th 2014, 10:17am

ASH Annual Meeting and Exposition

Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.

December 7th 2014, 6:37am

ASH Annual Meeting and Exposition

Treatment with the PD-1 inhibitor pembrolizumab generated responses in 66% of patients with heavily pretreated classical Hodgkin lymphoma.

December 7th 2014, 6:20am

ASH Annual Meeting and Exposition

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

December 6th 2014, 4:42pm

ASH Annual Meeting and Exposition

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

December 6th 2014, 4:04pm

ASH Annual Meeting and Exposition

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

December 6th 2014, 1:55pm

ASH Annual Meeting and Exposition

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

December 1st 2014, 2:46pm

ASH Annual Meeting and Exposition

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

December 1st 2014, 9:32am

ASH Annual Meeting and Exposition

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

November 18th 2014, 10:37am

PER® New York Lung Cancer Symposium

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

November 17th 2014, 12:16pm

Society for Neuro-Oncology Annual Meeting

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

November 17th 2014, 10:47am

Society for Neuro-Oncology Annual Meeting

Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses a study that analyzed the overall survival and toxicity of proton therapy for large-volume re-irradiation for recurrent glioma.

November 17th 2014, 9:25am

Society for Neuro-Oncology Annual Meeting

The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.

November 17th 2014, 8:23am

Society for Neuro-Oncology Annual Meeting

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

November 16th 2014, 1:08pm

Society for Neuro-Oncology Annual Meeting

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).

November 16th 2014, 12:22pm

Society for Neuro-Oncology Annual Meeting

Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.

November 16th 2014, 11:17am

Society for Neuro-Oncology Annual Meeting

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).